ACE inhibitors – Page 4 – Communicable Diseases Research

Bioinformatics and system biology approach to identify the influences of COVID-19 on cardiovascular and hypertensive comorbidities

심혈관 및 고혈압 동반 질환에 대한 COVID-19의 영향을 식별하기 위한 생물정보학 및 시스템 생물학 접근

Article

Published on 2021-03-222022-09-11
Journal: Briefings in Bioinformatics [Category] SARS, 유전자 메커니즘,

Antihypertensive Drugs and COVID-19 Risk: A Cohort Study of 2 Million Hypertensive Patients

Observational Study

Published on 2021-03-032022-10-05
Journal: Hypertension (Dallas, Tex. : 1979) [Category] SARS, 임상,

[키워드] ACE ACE inhibitor ACE inhibitors angiotensin receptor blocker Angiotensin receptor blockers Angiotensin-converting enzyme angiotensin-converting enzyme inhibitors antihypertensive ARB ARBs associations blocker calcium channel blockers cardiovascular disease CCB CCBs chronic respiratory disease Cohort coronavirus disease COVID-19 COVID-19 hospitalization database diabetes died drug end point Evidence examined excluded French hazard ratio Hospital stay Hospitalization Hospitalized hypertension hypertensive patient hypothese hypotheses inhibitor insurance Intubated limit lower risk Mortality Patient patients treated pharmacoepidemiology positive prevalent primary end point raise receptor renal risk treated
[DOI] 10.1161/HYPERTENSIONAHA.120.16314 PMC 바로가기 [Article Type] Observational Study

The effect of angiotensin-converting enzyme levels on COVID-19 susceptibility and severity: a Mendelian randomization study

COVID-19 감수성 및 중증도에 대한 지오텐신 전환 효소 수치의 영향: 멘델식 무작위 배정 연구

Article

Published on 2021-03-032022-09-11
Journal: International Journal of Epidemiology [Category] SARS, 변종,

[키워드] 95% CI 95% confidence interval ACE ACE gene ACE inhibitor ACE inhibitors Analysis angiotensin Angiotensin-converting enzyme angiotensin-converting enzyme. benefit Cohort cohorts COVID-19 COVID-19 disease COVID-19 pandemic COVID-19 severity COVID-19 susceptibility decrease European explain genetic determinant genetic determinants Genetic variant genetic variants Genome-wide association study GWAS Hospitalization Icelanders increase in individual inhibitor initiative Latino mendelian randomization observational studies Odds ratio outcome performed reducing SARS-COV-2 infection Sensitivity analyses serum severe disease severity susceptibility therapy These data Trial variance variant were used
[DOI] 10.1093/ije/dyaa229 PMC 바로가기 [Article Type] Article

Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update

COVID-19의 안지오텐신-전환-효소 2 및 레닌-안지오텐신 시스템 억제제: 업데이트

Review

Published on 2021-03-012022-09-11
Journal: High blood pressure & cardiovascular prevention : [Category] SARS, 치료제,

[키워드] ACE inhibitor ACE inhibitors ACE2 ACE2 gene ACEi acute respiratory distress syndrome affected aldosterone Analysis ANG-II angiotensin Angiotensin-converting enzyme angiotensin-converting enzyme 2 ARBs ARDS association benefit blocker candidate vaccine caused clinical study clinical trials Comorbidity component Corona COVID-19 COVID-19 infection decreased expression diabete diabetes Diabetes Mellitus dysfunction enzyme facilitate fatality high risk highlight host cell Human immune system hypertension individual inhibitor Interaction medication medications mortality rate outbreak patients with diabete progression RAS RAS inhibitors receptor Receptor Blockers receptors recombinant ACE2 regulate Renin renin-angiotensin-aldosterone system reported respiratory respiratory distress Respiratory distress syndrome SARS-CoV-2 SARS-CoV2 severe disease System target Therapies Treatment treatment of COVID-19 treatment strategy Virus Disease virus entry
[DOI] 10.1007/s40292-021-00439-9 PMC 바로가기 [Article Type] Review

Renin-Angiotensin-Aldosterone System Blockers Prior to Hospitalization and Their Association With Clinical Outcomes in Coronavirus Disease 2019 (COVID-19)

Cardiology

Published on 2021-02-182022-10-31
Journal: Cureus [Category] COVID-19,

Prospective meta-analysis protocol on randomised trials of renin-angiotensin system inhibitors in patients with COVID-19: an initiative of the International Society of Hypertension

COVID-19 환자를 대상으로 한 레닌-안지오텐신계 억제제의 무작위 시험에 대한 전향적 메타분석 프로토콜: 국제고혈압 학회(International Society of Hypertension)의 주도

Article

Published on 2021-02-162022-08-31
Journal: BMJ Open [Category] meta-analysis, 임상,

[키워드] ACE inhibitor ACE inhibitors ACEi ACEi/ARB Admission all-cause mortality Analysis Angiotensin II approval ARB ARBs Cardiology cardiovascular event Cardiovascular events clinical decision Comorbidities contribute Controlled controlled trials country COVID-19 Decision making drug Efficacy eligible Ethics Ethnicity Follow-up followed by Formal Guidance Health policy hypertension identify include inclusion criteria infected with SARS-CoV-2 Informed consent inhibitor initiated intensive care mechanical ventilation Meta-analysis occur outcome Patient patients with COVID-19 peer-reviewed performed Primary outcome Prospective protocol public health randomised randomised controlled trial Randomised controlled trials Randomised trial RCT RCTs receptor receptor blocker recruitment renin-angiotensin system responsibility secondary Secondary outcomes smoking smoking status Society study duration therapy Trial widespread
[DOI] 10.1136/bmjopen-2020-043625 PMC 바로가기 [Article Type] Article

Evaluation of the efficacy and safety of icatibant and C1 esterase/kallikrein inhibitor in severe COVID-19: study protocol for a three-armed randomized controlled trial

중증 코로나19 환자에서 이카티반트 및 C1 에스테라제/칼리크레인 억제제의 효능 및 안전성 평가: 3군 무작위 대조 시험 연구 프로토콜

Study Protocol

Published on 2021-01-202022-09-10
Journal: Trials [Category] 비임상, 임상,

[키워드] accumulation ACE inhibitor ACE inhibitors ACE2 angiotensin Angiotensin-converting enzyme angiotensin-converting enzyme 2 animal models anti-inflammatory agents antibiotic antithrombotic therapy assigned binding bradykinin breath C1 esterase inhibitor cause Cell clinical clinical trial clinical trials cough COVID-19 Degradation dependent on driving Efficacy and safety eligible patient expressed Icatibant inactivation include Inflammatory inhibitor intravenously invasive ventilation leads lipopolysaccharide LPS lung lung inflammatory response Lungs mechanism mortality rates Non-invasive number Open-label oxygen parallel-group Pneumonia Pneumonitis Prophylactic Protein randomized clinical trial Randomized controlled trial Randomly receive reduce registry renal replacement therapy replacement therapy Respiratory failure SARS-CoV-2 severe COVID-19 patient severe COVID-19 patients Severity of disease Side effect single-center standard care Study protocol subcutaneously supplemental oxygen the cells Universal vasopressor support viral-induced virus
[DOI] 10.1186/s13063-021-05027-9 PMC 바로가기 [Article Type] Study Protocol

Higher comorbidities and early death in hospitalized African-American patients with Covid-19

Research Article

Published on 2021-01-182022-10-28
Journal: BMC Infectious Diseases [Category] COVID-19, MERS,

[키워드] ACE ACE inhibitor ACE inhibitors Admission African-Americans Analysis angiotensin II receptor blockers ARBs benefit black body mass index Care cause Chronic kidney disease clinical feature Comorbidities Comorbidity consecutive patient Coronary artery disease COVID-19 COVID-19 patient Cox proportional hazard Critical CRP death demonstrated determine Diabetes Mellitus dialysis died Efficacy Escalation favorable effect Glucose groups Health Health disparities Hemodialysis Hospitalization Hospitalized identify in-hospital mortality independent predictor Inpatient Invasive mechanical ventilation Laboratory laboratory data LDH lower mortality majority morbidity and mortality Mortality New York City outcome outcomes pandemic Patient patients performed positive Predictive Prevalence procalcitonin prognostic Racial receive required Result retrospective cohort study significantly suffered supplementary material tested The United States treatment interventions was performed
[DOI] 10.1186/s12879-021-05782-9 PMC 바로가기 [Article Type] Research Article

The efficacy and safety of Ivermectin in patients with mild and moderate COVID-19: A structured summary of a study protocol for a randomized controlled trial

경증 및 중등도 COVID-19 환자에서 이버멕틴의 효능 및 안전성: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2021-01-042022-09-10
Journal: Trials [Category] 임상, 치료제,

[키워드] 1:1 ACE inhibitor ACE inhibitors acute respiratory syndrome Adverse drug reaction Adverse drug reactions AIDS allergy anticipated Anticoagulant Anticoagulants Asthma Bandar Abbas Blinding Breastfeeding Captopril chest X-ray clinical clinical symptom Clinical symptoms clinical trial clinical trials company Computed tomography Confirmed Control control group control groups Controlled trial COVID-19 COVID-19 symptom criteria Critical CXR Department discharge Diseases dissemination dose Drug allergy education Efficacy and safety element evaluate exclusion criteria FIVE France group groups history Hospital stay Hospitalization Hospitalization Mechanical ventilation hydroxychloroquine sulfate ICU admission incidence include inclusion criteria India Infection Informed consent Inpatients Interferon beta-1a intervention group Iran Ivermectin Kidney disease liver loiasis Lopinavir Lopinavir/ritonavir mechanical ventilation Mild mild COVID-19 symptom mild COVID-19 symptoms mild pneumonia Ministry of Health moderate Moderate COVID-19 moderately severe COVID-19 MSD number objective Open-label Other outcome Outpatient outpatients parallel-group participant Patient patients patients with moderate PCR pharmaceutical Pharmaceutical Company Phase 3 Pneumonia Pregnancy Primary outcome Primary outcomes protocol random randomization Randomized Randomized controlled trial receive regimen Registered registration date registration number registry respiratory Ritonavir routine care Sample size secondary outcome selected Seven Severe acute respiratory syndrome single dose single-center standard treatment status Study protocol subsequent supplementary material table the patient Treatment treatment group Trial registration twice a day two group two groups underlying diseases Version Warfarin website weight
[DOI] 10.1186/s13063-020-04988-7 PMC 바로가기 [Article Type] Letter

ACE inhibitors, angiotensin receptor blockers and endothelial injury in COVID‐19

Original Article

Published on 2020-12-062023-06-16
Journal: Journal of Internal Medicine [Category] MERS, SARS,

[키워드] ACE inhibitors Critical care endothelial function Infectious disease renal failure thrombosis
[DOI] 10.1111/joim.13202 PMC 바로가기 [Article Type] Original Article